Reactive oxygen species production by blood leukocytes and its correction by trimetazidine MB in patients with acute coronary syndrome
Aim. In patients with acute coronary syndrome (ACS), to detect pre-activated (primed) phagocytes in peripheral blood and to evaluate the effects of trimetazidine MB, when added to standard therapy, on reactive oxygen species (ROS) production. Material and methods. In 113 hospitalised ACS patients –...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2009-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1354 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849342163367755776 |
|---|---|
| author | M. G. Glezer S. V. Kulikov R. T. Saygitov E. I. Astashkin |
| author_facet | M. G. Glezer S. V. Kulikov R. T. Saygitov E. I. Astashkin |
| author_sort | M. G. Glezer |
| collection | DOAJ |
| description | Aim. In patients with acute coronary syndrome (ACS), to detect pre-activated (primed) phagocytes in peripheral blood and to evaluate the effects of trimetazidine MB, when added to standard therapy, on reactive oxygen species (ROS) production. Material and methods. In 113 hospitalised ACS patients – 86 with myocardial infraction (MI) and 27 with unstable angina (UA) – the dynamics of blood leukocytes and ROS (baseline activity and PMA (phorbol-12-myristate-13-acetate) stimulated activity) was assessed by lucigen-dependent chemiluminescence method. In 60 participants, trimetazidine MB (70 mg/d) effects on ROS production were investigated. Results. At hospital admission, blood leukocyte levels, basal and PMA-stimulated ROS production were significantly higher in AMI patients (especially in those who subsequently died) than in UA participants. Trimetazidine MB therapy facilitated more rapid and manifested leukocyte count reduction, compared to the standard therapy alone: the respective reductions at Days 3-5, 7-10, and 15-21 were -20 vs. -14%, -37 vs. -30%, and -47 vs. -32%. In the trimetazidine MB group, the basal and PMA-stimulated ROS production did not change significantly, while in the standard therapy group, the ROS production increased from Day 3 to Day 15.Conclusion. Adding trimetazidine MB to standard therapy of ACS patients significantly reduced the peripheral blood leukocyte count at Days 15-21, without leukocyte activation in the sub-acute phase of myocardial ischemia. |
| format | Article |
| id | doaj-art-d4d451f6e46f4ee19bd795a059cd0089 |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2009-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-d4d451f6e46f4ee19bd795a059cd00892025-08-20T03:43:27Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252009-08-018825291064Reactive oxygen species production by blood leukocytes and its correction by trimetazidine MB in patients with acute coronary syndromeM. G. Glezer0S. V. Kulikov1R. T. Saygitov2E. I. Astashkin3Research Centre, I.M. Sechenov Moscow Medical AcademyCity Clinical Hospital No. 59City Clinical Hospital No. 59Research Centre, I.M. Sechenov Moscow Medical AcademyAim. In patients with acute coronary syndrome (ACS), to detect pre-activated (primed) phagocytes in peripheral blood and to evaluate the effects of trimetazidine MB, when added to standard therapy, on reactive oxygen species (ROS) production. Material and methods. In 113 hospitalised ACS patients – 86 with myocardial infraction (MI) and 27 with unstable angina (UA) – the dynamics of blood leukocytes and ROS (baseline activity and PMA (phorbol-12-myristate-13-acetate) stimulated activity) was assessed by lucigen-dependent chemiluminescence method. In 60 participants, trimetazidine MB (70 mg/d) effects on ROS production were investigated. Results. At hospital admission, blood leukocyte levels, basal and PMA-stimulated ROS production were significantly higher in AMI patients (especially in those who subsequently died) than in UA participants. Trimetazidine MB therapy facilitated more rapid and manifested leukocyte count reduction, compared to the standard therapy alone: the respective reductions at Days 3-5, 7-10, and 15-21 were -20 vs. -14%, -37 vs. -30%, and -47 vs. -32%. In the trimetazidine MB group, the basal and PMA-stimulated ROS production did not change significantly, while in the standard therapy group, the ROS production increased from Day 3 to Day 15.Conclusion. Adding trimetazidine MB to standard therapy of ACS patients significantly reduced the peripheral blood leukocyte count at Days 15-21, without leukocyte activation in the sub-acute phase of myocardial ischemia.https://cardiovascular.elpub.ru/jour/article/view/1354acute coronary syndromeleukocytesreactive oxygen speciestrimetazidine |
| spellingShingle | M. G. Glezer S. V. Kulikov R. T. Saygitov E. I. Astashkin Reactive oxygen species production by blood leukocytes and its correction by trimetazidine MB in patients with acute coronary syndrome Кардиоваскулярная терапия и профилактика acute coronary syndrome leukocytes reactive oxygen species trimetazidine |
| title | Reactive oxygen species production by blood leukocytes and its correction by trimetazidine MB in patients with acute coronary syndrome |
| title_full | Reactive oxygen species production by blood leukocytes and its correction by trimetazidine MB in patients with acute coronary syndrome |
| title_fullStr | Reactive oxygen species production by blood leukocytes and its correction by trimetazidine MB in patients with acute coronary syndrome |
| title_full_unstemmed | Reactive oxygen species production by blood leukocytes and its correction by trimetazidine MB in patients with acute coronary syndrome |
| title_short | Reactive oxygen species production by blood leukocytes and its correction by trimetazidine MB in patients with acute coronary syndrome |
| title_sort | reactive oxygen species production by blood leukocytes and its correction by trimetazidine mb in patients with acute coronary syndrome |
| topic | acute coronary syndrome leukocytes reactive oxygen species trimetazidine |
| url | https://cardiovascular.elpub.ru/jour/article/view/1354 |
| work_keys_str_mv | AT mgglezer reactiveoxygenspeciesproductionbybloodleukocytesanditscorrectionbytrimetazidinembinpatientswithacutecoronarysyndrome AT svkulikov reactiveoxygenspeciesproductionbybloodleukocytesanditscorrectionbytrimetazidinembinpatientswithacutecoronarysyndrome AT rtsaygitov reactiveoxygenspeciesproductionbybloodleukocytesanditscorrectionbytrimetazidinembinpatientswithacutecoronarysyndrome AT eiastashkin reactiveoxygenspeciesproductionbybloodleukocytesanditscorrectionbytrimetazidinembinpatientswithacutecoronarysyndrome |